216 related articles for article (PubMed ID: 15305466)
1. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
Traino AC; Di Martino F; Lazzeri M
Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
[TBL] [Abstract][Full Text] [Related]
2. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
3. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
Traino AC; Grosso M; Mariani G
Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
[TBL] [Abstract][Full Text] [Related]
4. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity.
Carlier T; Salaun PY; Cavarec MB; Valette F; Turzo A; Bardiès M; Bizais Y; Couturier O
Nucl Med Commun; 2006 Jul; 27(7):559-66. PubMed ID: 16794516
[TBL] [Abstract][Full Text] [Related]
5. Study of the correlation between administered activity and radiation committed dose to the thyroid in 131I therapy of Graves' disease.
Traino AC; Di Martino F; Lazzeri M; Stabin MG
Radiat Prot Dosimetry; 2001; 95(2):117-24. PubMed ID: 11572639
[TBL] [Abstract][Full Text] [Related]
6. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
[TBL] [Abstract][Full Text] [Related]
7. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
[TBL] [Abstract][Full Text] [Related]
8. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
[TBL] [Abstract][Full Text] [Related]
9. Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism.
Traino AC; Di Martino F; Lazzeri M; Stabin MG
Phys Med Biol; 2000 Jan; 45(1):121-9. PubMed ID: 10661587
[TBL] [Abstract][Full Text] [Related]
10. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131.
Brill AB; Stabin M; Bouville A; Ron E
Radiat Res; 2006 Jul; 166(1 Pt 2):128-40. PubMed ID: 16808602
[TBL] [Abstract][Full Text] [Related]
11. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.
Traino AC; Xhafa B
Med Phys; 2009 Apr; 36(4):1212-8. PubMed ID: 19472628
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
15. Planning of 131I therapy for graves disease based on the radiation dose to thyroid follicular cells.
Eterovic D; Antunovic Z; Markovic V; Grosev D
J Nucl Med; 2008 Dec; 49(12):2026-30. PubMed ID: 18997041
[TBL] [Abstract][Full Text] [Related]
16. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
[TBL] [Abstract][Full Text] [Related]
17. Single dose planning for radioiodine-131 therapy of Graves' disease.
Kita T; Yokoyama K; Kinuya S; Taki J; Michigishi T; Tonami N
Ann Nucl Med; 2004 Apr; 18(2):151-5. PubMed ID: 15195763
[TBL] [Abstract][Full Text] [Related]
18. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.
Willegaignon J; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2013 Apr; 38(4):231-6. PubMed ID: 23429386
[TBL] [Abstract][Full Text] [Related]
20. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
